FREQUENCY AND COSTS ASSOCIATED WITH TARGETED THERAPY-RELATED ADVERSE EVENTS (AES) DURING FIRST AND SECOND LINE OF TREATMENT (LOT) AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Byfield, DaCosta S. [1 ]
Langer, C. [2 ]
Ogale, S. [2 ]
Morlock, R. [2 ]
机构：
[1] Optum, Eden Prairie, MN USA
[2] Genentech Inc, San Francisco, CA 94080 USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN75
引用
收藏
页码：A80 / A81
页数：2
相关论文
共 50 条
  • [1] ADVERSE EVENTS (AES) ASSOCIATED WITH BEVACIZUMAB (BV) IN OLDER PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Shankaran, V.
    Mummy, D.
    Koepl, L.
    Blough, D.
    Yim, Y. M.
    Yu, E.
    Ramsey, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 203 - 203
  • [2] Age-related disparity in treatment outcome and adverse events among patients with metastatic colorectal cancer (mCRC).
    Meng, Lingbin
    Thapa, Ram
    Xie, Hao
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [3] Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US)
    Latremouille-Viau, Dominick
    Chang, Jane
    Guerin, Annie
    Shi, Sherry
    Wang, Ed
    Yu, Justin
    Ngai, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Economic burden of common adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US)
    Latremouille-Viau, Dominick
    Chang, Jane
    Guerin, Annie
    Shi, Sherry
    Wang, Ed
    Yu, Justin
    Ngai, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07)
  • [5] LOW USE OF BIOLOGICS IN FIRST-LINE THERAPY AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
    Klink, A. J.
    Nabhan, C.
    Ernst, F. R.
    Feinberg, B. A.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A129 - A129
  • [6] Serious adverse events among a population-based cohort of patients receiving first-line chemotherapy for metastatic colorectal cancer (mCRC)
    Jang, Raymond Woo-Jun
    Enright, Katherine
    Booth, Christopher M.
    Chan, Kelvin K.
    Yun, Lingsong
    Krzyzanowska, Monika K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT FOR METASTATIC COLORECTAL CANCER
    Fu, A. Z.
    Zhao, Z.
    Wang, S.
    Gao, S.
    Barber, B.
    Liu, G.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A173 - A173
  • [8] Treatment patterns and costs in second-line (2L) metastatic colorectal cancer (mCRC)
    Teitelbaum, April H.
    Evans, Dana
    Yu, Elaine
    Morlock, Robert
    Byfield, Stacey DaCosta
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [9] Disparity of treatment-related adverse events and outcome in patients with early-onset metastatic colorectal cancer (mCRC).
    Meng, Lingbin
    Thapa, Ram
    Kim, Richard D.
    Laber, Damian A.
    Xie, Hao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Capecitabine and oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (MCRC)
    Karacetin, D.
    Maral, O.
    Yalcyn, B.
    Okten, B.
    Incekara, O.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
12345